Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells.

[1]  G. Pagès,et al.  Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides. , 2017, Bioorganic & medicinal chemistry letters.

[2]  R. Benhida,et al.  Assessment of new triplet forming artificial nucleobases as RNA ligands directed towards HCV IRES IIId loop. , 2017, Bioorganic & medicinal chemistry letters.

[3]  R. Benhida,et al.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. , 2017, MedChemComm.

[4]  G. Robert,et al.  In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies. , 2017, Journal of medicinal chemistry.

[5]  R. Benhida,et al.  Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories. , 2017, MedChemComm.

[6]  S. Rocchi,et al.  Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges , 2017, Medicinal research reviews.

[7]  S. Rocchi,et al.  Targeting BIP to induce Endoplasmic Reticulum stress and cancer cell death , 2016, Oncoscience.

[8]  R. Wolff,et al.  Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? , 2016, Journal of oncology practice.

[9]  Palmi Modi,et al.  Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives. , 2016, Current topics in medicinal chemistry.

[10]  P. Abbe,et al.  Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells. , 2016, Journal of medicinal chemistry.

[11]  P. Abbe,et al.  Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. , 2016, Cancer cell.

[12]  M. Duca,et al.  Oncogenic MicroRNAs Biogenesis as a Drug Target: Structure-Activity Relationship Studies on New Aminoglycoside Conjugates. , 2016, Chemistry.

[13]  S. Na'ara,et al.  Gemcitabine resistance in pancreatic ductal adenocarcinoma. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  R. Benhida,et al.  Efficient and selective azidation of per-O-acetylated sugars using ultrasound activation: application to the one-pot synthesis of 1,2,3-triazole glycosides , 2015 .

[15]  C. Tanyeli,et al.  Bioactive thiazole and benzothiazole derivatives. , 2015, European journal of medicinal chemistry.

[16]  Yu-hong Yuan,et al.  Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis , 2015, American journal of clinical oncology.

[17]  J. Utikal,et al.  New therapeutic options for advanced non-resectable malignant melanoma. , 2015, Advances in medical sciences.

[18]  N. Hayward,et al.  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.

[19]  T. Schumacher,et al.  Acquired and intrinsic resistance in cancer immunotherapy , 2014, Molecular oncology.

[20]  K. Smalley,et al.  Resistance to Raf inhibition in cancer. , 2014, Drug discovery today. Technologies.

[21]  M. Duca,et al.  Artificial nucleobase-amino acid conjugates: a new class of TAR RNA binding agents. , 2014, Chemistry.

[22]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[23]  G. Robert,et al.  Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis. , 2012, Ultrasonics sonochemistry.

[24]  C. Robert,et al.  New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.

[25]  M. Duca,et al.  Design of novel RNA ligands that bind stem-bulge HIV-1 TAR RNA. , 2010, Chemical communications.

[26]  J. Balzarini,et al.  Efficient synthesis and in vitro cytostatic activity of 4-substituted triazolyl-nucleosides. , 2007, Bioorganic & medicinal chemistry letters.

[27]  Jian-sheng Sun,et al.  Design of artificial nucleobases for the recognition of the AT inversion by triple-helix forming oligonucleotides: a structure-stability relationship study and neighbour bases effect. , 2003, Bioorganic & medicinal chemistry.

[28]  M. D’Incalci,et al.  Mechanisms of resistance to alkylating agents , 1998, Cytotechnology.

[29]  G. Robert,et al.  FeCl3-promoted and ultrasound-assisted synthesis of resveratrol O-derived glycoside analogs. , 2015, Ultrasonics sonochemistry.

[30]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[31]  W. Dalton,et al.  De Novo and Acquired Resistance to Antitumor Alkylating Agents , 2006 .

[32]  Beverly A. Teicher,et al.  Cancer Drug Resistance , 2006 .

[33]  R. Benhida,et al.  Incorporation of a novel nucleobase allows stable oligonucleotide-directed triple helix formation at the target sequence containing a purine.pyrimidine interruption. , 2001, Chemical communications.